Company news

BiomX Inc. news in 2025

BiomX Inc.'s news releases, calls and decks from 2025, newest first.

View company

BiomX Announces $3.0 Million Private Placement

December 29, 2025

BiomX Announces Discontinuation of Phase 2b BX004 Trial Following Internal Review

December 8, 2025

BiomX Provides Update on BX004 Phase 2b Trial in Cystic Fibrosis

November 25, 2025

BiomX Inc. Announces 1-for-19 Reverse Stock Split

November 14, 2025

BiomX Reports Third Quarter 2025 Financial Results and Provides Program Updates

November 12, 2025

BiomX to Report Third Quarter 2025 Financial Results and Program Updates on November 12, 2025

November 5, 2025

BiomX Announces Positive FDA Feedback Supporting Next-Generation Phage Cocktail Program for Diabetic Foot Infections

November 4, 2025

BiomX Provides a Program Update and Announces New FDA Feedback Potentially Expanding BX004 Development Pathways

October 17, 2025

BiomX CEO to Present at H.C. Wainwright 27th Annual Global Investment Conference

September 4, 2025

BiomX Provides Update on BX004 Phase 2b Trial for the Treatment of Patients with Cystic Fibrosis

August 19, 2025

BiomX Reports Second Quarter 2025 Financial Results and Provides Program Updates

August 13, 2025

BiomX to Report Second Quarter 2025 Financial Results and Program Updates on August 13, 2025

August 6, 2025

BiomX Announces Successful Initiation of Phase 2b Trial with First Patient Dosed in BX004 Program in Patients with Cystic Fibrosis

July 14, 2025

BiomX Announces Publication in Nature Communications of Phage Cocktail BX004 Phase 1b/2a Part 1 Data Demonstrating Strong Activity in Cystic Fibrosis

July 8, 2025

BiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 Conference

May 19, 2025

BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates

May 15, 2025

BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025

May 8, 2025

Calls in 2025

Decks in 2025